Evaluating Graves' orbitopathy
- PMID: 22632361
- DOI: 10.1016/j.beem.2011.11.007
Evaluating Graves' orbitopathy
Abstract
Graves' Orbitopathy (GO) is an immune-mediated disorder causing inflammation and expansion of orbital fat and muscle. The resulting spectrum of ocular and orbital changes may cause significant visual and cosmetic morbidity and are graded as disease severity. The disease follows a biphasic course with an active or progressive phase followed by a quiescent or stable phase: the temporal status is graded as disease activity. Grading systems for GO include Werner's NO SPECS and European Group on Graves' Orbitopathy (EUGOGO)'s severity scales, the Clinical Activity Score (CAS) and the VISA Classification (for severity and activity). Diagnosis of GO is based on recognition of clinical features and may be supported by thyroid function and immune testing, and orbital imaging. The endocrinologist or internist may play an important role in early recognition and diagnosis of GO, in grading severity and activity, and in arranging appropriate referral to an ophthalmologist based on this evaluation.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Optimal management of Graves orbitopathy: a multidisciplinary approach.Neth J Med. 2011 Jul-Aug;69(7):302-8. Neth J Med. 2011. PMID: 21934174 Review.
-
[Diagnosis and treatment of dysthyroid orbitopathy: a multidisciplinary disease].J Fr Ophtalmol. 2013 Dec;36(10):874-85. doi: 10.1016/j.jfo.2013.07.004. Epub 2013 Nov 15. J Fr Ophtalmol. 2013. PMID: 24239215 Review. French.
-
Graves'-like orbitopathy in a patient with chronic autoimmune pancreatitis.Thyroid. 2011 Dec;21(12):1389-92. doi: 10.1089/thy.2011.0191. Epub 2011 Nov 8. Thyroid. 2011. PMID: 22066480
-
Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].Endokrynol Pol. 2022;73(4):756-777. doi: 10.5603/EP.a2022.0040. Endokrynol Pol. 2022. PMID: 36059167 English.
-
[Graves' orbitopathy].Klin Monbl Augenheilkd. 2011 May;228(5):432-8. doi: 10.1055/s-0031-1273366. Epub 2011 Apr 29. Klin Monbl Augenheilkd. 2011. PMID: 21534176 Review. German.
Cited by
-
Prevalence and natural history of Graves' orbitopathy in the XXI century.J Endocrinol Invest. 2013 Jun;36(6):444-9. doi: 10.3275/8937. Epub 2013 Apr 16. J Endocrinol Invest. 2013. PMID: 23587873 Review.
-
Absent Bell's phenomenon in patients with thyroid eye disease.BMC Ophthalmol. 2021 Oct 11;21(1):361. doi: 10.1186/s12886-021-02107-x. BMC Ophthalmol. 2021. PMID: 34635084 Free PMC article.
-
BIOINFORMATIC ANALYSIS IDENTIFIES POTENTIALLY KEY DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN ORBITAL ADIPOSE TISSUES OF PATIENTS WITH THYROID EYE DISEASE.Acta Endocrinol (Buchar). 2019 Jan-Mar;-5(1):1-8. doi: 10.4183/aeb.2019.1. Acta Endocrinol (Buchar). 2019. PMID: 31149053 Free PMC article.
-
99Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy.Eye (Lond). 2017 May;31(5):668-676. doi: 10.1038/eye.2017.42. Epub 2017 Apr 7. Eye (Lond). 2017. PMID: 28387769 Free PMC article.
-
Choroidal thickness in thyroid eye disease and its correlation with disease activity.Indian J Ophthalmol. 2024 Feb 1;72(2):281-286. doi: 10.4103/IJO.IJO_848_23. Epub 2023 Dec 26. Indian J Ophthalmol. 2024. PMID: 38146970 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous